Key Points
- CFO Stephen Carey sold 7,312 shares on March 5 at an average price of $75.50 for $552,056, reducing his stake by 3.79% to 185,543 shares (worth about $14.0M).
- ANI shares fell 2.4% to $73.80 on light volume (37,901 vs. a 449,160 average), with a 12‑month range of $56.71–$99.50 and a market cap of about $1.66 billion.
- Analyst sentiment is mildly positive: consensus is a "Moderate Buy" with a $103.43 average price target (six Buys, three Holds), including recent upgrades and raised targets from firms like Guggenheim and Barclays.
ANI Pharmaceuticals, Inc. (NASDAQ:ANIP - Get Free Report) CFO Stephen Carey sold 7,312 shares of the firm's stock in a transaction that occurred on Thursday, March 5th. The stock was sold at an average price of $75.50, for a total transaction of $552,056.00. Following the sale, the chief financial officer owned 185,543 shares in the company, valued at approximately $14,008,496.50. This trade represents a 3.79% decrease in their position. The sale was disclosed in a legal filing with the SEC, which is available through this hyperlink.
ANI Pharmaceuticals Trading Down 2.4%
ANIP traded down $1.80 during trading on Friday, hitting $73.80. The company's stock had a trading volume of 37,901 shares, compared to its average volume of 449,160. ANI Pharmaceuticals, Inc. has a twelve month low of $56.71 and a twelve month high of $99.50. The stock has a market cap of $1.66 billion, a PE ratio of 21.96 and a beta of 0.52. The firm's 50 day moving average price is $79.83 and its 200-day moving average price is $86.04. The company has a debt-to-equity ratio of 1.11, a current ratio of 2.71 and a quick ratio of 2.19.
Analyst Upgrades and Downgrades
A number of research firms have recently commented on ANIP. Weiss Ratings reaffirmed a "hold (c+)" rating on shares of ANI Pharmaceuticals in a research note on Monday, December 29th. Barclays initiated coverage on shares of ANI Pharmaceuticals in a report on Tuesday, December 9th. They issued an "overweight" rating and a $100.00 target price for the company. Zacks Research downgraded shares of ANI Pharmaceuticals from a "strong-buy" rating to a "hold" rating in a research note on Tuesday, January 6th. Finally, Guggenheim boosted their price objective on shares of ANI Pharmaceuticals from $115.00 to $124.00 and gave the company a "buy" rating in a research note on Friday, January 16th. Six research analysts have rated the stock with a Buy rating and three have given a Hold rating to the company. According to MarketBeat.com, ANI Pharmaceuticals has a consensus rating of "Moderate Buy" and a consensus price target of $103.43.
Read Our Latest Research Report on ANIP
Institutional Inflows and Outflows
Institutional investors have recently modified their holdings of the business. GAMMA Investing LLC increased its position in ANI Pharmaceuticals by 9.1% in the 3rd quarter. GAMMA Investing LLC now owns 1,505 shares of the specialty pharmaceutical company's stock valued at $138,000 after acquiring an additional 126 shares during the period. Maryland State Retirement & Pension System increased its holdings in shares of ANI Pharmaceuticals by 5.4% during the fourth quarter. Maryland State Retirement & Pension System now owns 2,613 shares of the specialty pharmaceutical company's stock valued at $206,000 after purchasing an additional 134 shares during the period. Illinois Municipal Retirement Fund raised its stake in shares of ANI Pharmaceuticals by 1.7% during the third quarter. Illinois Municipal Retirement Fund now owns 8,538 shares of the specialty pharmaceutical company's stock valued at $782,000 after purchasing an additional 145 shares in the last quarter. Amalgamated Bank lifted its holdings in ANI Pharmaceuticals by 3.1% in the third quarter. Amalgamated Bank now owns 5,066 shares of the specialty pharmaceutical company's stock worth $464,000 after purchasing an additional 154 shares during the period. Finally, CANADA LIFE ASSURANCE Co grew its position in ANI Pharmaceuticals by 1.0% in the 2nd quarter. CANADA LIFE ASSURANCE Co now owns 19,408 shares of the specialty pharmaceutical company's stock valued at $1,267,000 after buying an additional 198 shares in the last quarter. Institutional investors and hedge funds own 76.05% of the company's stock.
ANI Pharmaceuticals Company Profile
(
Get Free Report)
ANI Pharmaceuticals, Inc is a United States–based specialty pharmaceutical company focused on the development, manufacturing and commercialization of generic and branded prescription drugs. The company operates as an end-to-end provider, offering services that range from active pharmaceutical ingredient (API) production and formulation development to finished dosage form manufacturing and packaging.
ANI's product portfolio encompasses injectable and oral therapies across several therapeutic areas, including endocrinology, oncology, pain management and respiratory care.
Featured Stories
This instant news alert was generated by narrative science technology and financial data from InsiderTrades.com in order to provide readers with the fastest and most accurate reporting. Please send any questions or comments about this story to [email protected].
